Valeant wins FDA approval for Siliq
Valeant Pharmaceuticals International Inc. won a widely anticipated FDA approval for its moderate to severe plaque psoriasis drug, Siliq (brodalumab), complete with an expected black box warning for suicidal ideation and behavior that analysts expect could hamper sales. U.S. availability of the drug, licensed from Astrazeneca plc, is set for the second half of this year. Acceptance of the drug's EMA marketing authorization application arrived in late 2015.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST